Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Extracellular matrix components in preeclampsia.
Clin Chim Acta
January 2025
Biochemistry Department, Centro Universitário Faculdade de Medicina ABC (FMABC), Santo André, São Paulo, Brazil.
Preeclampsia (PE) is a gestational complication affecting 5% to 10% of all pregnancies. PE is characterized by hypertension and endothelial dysfunction, whose etiology involves, among other factors, alterations in the extracellular matrix (ECM) that can compromise vascular remodeling and trophoblast invasion, ie, processes essential for placental development. Endothelial dysfunction is caused by release of antiangiogenic factors, mainly a soluble fms-like tyrosine kinase-1 (sFlt-1), which antagonizes two endothelial angiogenic factors, the vascular endothelial growth factor (VEGF) and placental growth factor (PLGF).
View Article and Find Full Text PDFPoint-of-Care Tests for Preeclampsia: Systematic Review and Meta-Analysis of Diagnostic Test Accuracy Studies.
BJOG
December 2024
Fetal Medicine Unit, St George's University Hospital, London, UK.
Article Synopsis
- Preeclampsia is a condition with serious risks for mothers and babies, and new angiogenic markers are being used to help diagnose it quickly in clinical settings.
- The study analyzed the effectiveness of various point-of-care tests for predicting preeclampsia, focusing on their sensitivity and specificity based on data from 17 relevant studies.
- Glycosylated fibronectin testing showed promising results with a sensitivity of 0.80 and specificity of 0.84, indicating it could be a valuable tool for clinical decisions regarding preeclampsia in high-risk patients.
Glycosylated fibronectin as a biomarker for preeclampsia and preeclampsia-related complications.
Pregnancy Hypertens
December 2024
Department of Gynecology and Obstetrics, Erasmus MC University Hospital, Rotterdam, the Netherlands.
Objectives: To evaluate glycosylated fibronectin (GlyFn) as a novel biomarker for preeclampsia and preeclampsia-related complications, and to compare GlyFn to traditional biomarkers, including soluble Fms-like tyrosine kinase-1 (sFlt-1) and placental growth factor (PlGF).
Study Design: Secondary analysis of a prospective cohort study (n = 524) with suspected preeclampsia (control), gestational hypertension (GH), or confirmed preeclampsia/hemolysis, elevated liver enzymes and low platelets syndrome (PE/HELLP).
Main Outcome Measures: GlyFn levels in PE/HELLP versus control and GH.
Publisher Correction: Fetal fibronectin (Quick Check fFN test) for detection of premature rupture of fetal membranes.
Arch Gynecol Obstet
December 2024
Department of Obstetrics and Gynecology, Ain Shams University, Abbassia, Cairo, Egypt.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!